Qualitative evaluation of adjuvant activities and its application to Th2/17 diseases

International Archives of Allergy and Immunology

Volumn 155, Issue SUPPL. 1, 2011, Pages 2-5

  Matsushita, Sho ^a   Takagi, Rie ^a   Hashimoto, Kumiko ^a   Higashi, Takehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvants; Atopic dermatitis; cAMP; Experimental autoimmune encephalomyelitis; Notch ligands

Indexed keywords

8 BROMO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; ALLERGEN; COENZYME A; CURDLAN; CYCLIC AMP; CYTOKINE; DOPAMINE 1 RECEPTOR; FORSKOLIN; IMMUNOLOGICAL ADJUVANT; LIGAND; LIPOPOLYSACCHARIDE; NOTCH RECEPTOR; PROBIOTIC AGENT; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ATOPIC DERMATITIS; CELL VIABILITY; CONFERENCE PAPER; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; MIXED LYMPHOCYTE REACTION; MOLECULAR WEIGHT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; QUALITATIVE ANALYSIS; RESPIRATORY TRACT MUCOSA; TH17 CELL; TH2 CELL; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DERMATITIS, ATOPIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNE SYSTEM DISEASES; TH17 CELLS; TH2 CELLS;

EID: 79958100220     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000327254     Document Type: Conference Paper

References (9)

1. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA: Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell 2004;117:515-526. (Pubitemid 38610236)
2. Wakui M, Nakano K, Matsushita S: Notch ligand mRNA levels of human APCs predict Th1/Th2-promoting activities. Biochem Biophys Res Commun 2007;358:596-601. (Pubitemid 46755746)
3. Higashi T, Hashimoto K, Takagi R, Mizuno Y, Okazaki Y, Tanaka Y, Matsushita S: Curdlan induces DC-mediated Th17 polarization via Jagged1 activation in human dendritic cells. Allergol Int 2010;59:161-166.
4. Higashi T, Wakui M, Nakano K, Hashimoto K, Takagi R, Tanaka Y, Matsushita S: Evaluation of adjuvant activities using human antigen presenting cells in vitro. Allergol Int 2008;57:219-222.
5. Takagi R, Higashi T, Hashimoto K, Nakano K, Mizuno Y, Okazaki Y, Matsushita S: B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones. J Immunol 2008;181:186-189.
6. Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S: Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2008;373:286-291.
7. Hashimoto K, Inoue T, Higashi T, Takei S, Awata T, Katayama S, Takagi R, Okada H, Matsushita S: Dopamine D1-like receptor antagonist, SCH23390, exhibits a preventive effect on diabetes mellitus that occurs naturally in NOD mice. Biochem Biophys Res Commun 2009;383:460-463.
8. Okada H, Inoue T, Hashimoto K, Suzuki H, Matsushita S: D1-like receptor antagonist inhibits IL-17 expression and attenuates crescent formation in nephrotoxic serum nephritis. Am J Nephrol 2009;30:274-279.
9. Nakashioya H, Nakano K, Watanabe N, Miyasaka N, Matsushita S, Kohsaka H: Therapeutic effect of D1-like dopamine receptor antagonist on collagen-induced arthritis of mice. Modern Rheumatol, in press.